219 related articles for article (PubMed ID: 38293085)
21. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
[TBL] [Abstract][Full Text] [Related]
22. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
[TBL] [Abstract][Full Text] [Related]
23. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
Xiao Q; Nobre A; Piñeiro P; Berciano-Guerrero MÁ; Alba E; Cobo M; Lauschke VM; Barragán I
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31968651
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
[TBL] [Abstract][Full Text] [Related]
25. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
26. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.
McGrail DJ; Pilié PG; Dai H; Lam TNA; Liang Y; Voorwerk L; Kok M; Zhang XH; Rosen JM; Heimberger AB; Peterson CB; Jonasch E; Lin SY
Sci Transl Med; 2021 Oct; 13(617):eabe6201. PubMed ID: 34705519
[TBL] [Abstract][Full Text] [Related]
27. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
Front Immunol; 2022; 13():872295. PubMed ID: 35634282
[TBL] [Abstract][Full Text] [Related]
29. Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidates.
Lang F; Sorn P; Schrörs B; Weber D; Kramer S; Sahin U; Löwer M
iScience; 2023 Nov; 26(11):108014. PubMed ID: 37965155
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy.
Lee J; Kim EH
Front Oncol; 2023; 13():1233376. PubMed ID: 37614504
[TBL] [Abstract][Full Text] [Related]
31. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma.
Cheung CCL; Seah YHJ; Fang J; Orpilla NHC; Lau MC; Lim CJ; Lim X; Lee JNLW; Lim JCT; Lim S; Cheng Q; Toh HC; Choo SP; Lee SY; Lee JJX; Liu J; Lim TKH; Tai D; Yeong J
Front Immunol; 2023; 14():1150985. PubMed ID: 37342338
[TBL] [Abstract][Full Text] [Related]
33. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade.
Lei Y; Li X; Huang Q; Zheng X; Liu M
Front Oncol; 2021; 11():617335. PubMed ID: 33777757
[TBL] [Abstract][Full Text] [Related]
34. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
35. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
Zheng M
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
[TBL] [Abstract][Full Text] [Related]
36. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment.
Luo H; Wang W; Mai J; Yin R; Cai X; Li Q
Front Immunol; 2023; 14():1267918. PubMed ID: 37881432
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM; Lee RY; Goh S; Tay ISY; Lim X; Lee B; Chew V; Li H; Tan B; Lim S; Lim JCT; Au B; Loh JJH; Saraf S; Connolly JE; Loh T; Leow WQ; Lee JJX; Toh HC; Malavasi F; Lee SY; Chow P; Newell EW; Choo SP; Tai D; Yeong J; Lim TKH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847986
[TBL] [Abstract][Full Text] [Related]
38. Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
De Wispelaere W; Annibali D; Tuyaerts S; Lambrechts D; Amant F
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922556
[TBL] [Abstract][Full Text] [Related]
39. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.
Yang M; Lin C; Wang Y; Chen K; Zhang H; Li W
Genome Med; 2022 Jul; 14(1):72. PubMed ID: 35799269
[TBL] [Abstract][Full Text] [Related]
40. Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors.
Reil KA; Tsuji S; Molina E; Nelson KL; McGuire KL; Giacalone MJ
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37290924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]